2,4-thiazolidinedione has been researched along with Hyperparathyroidism in 1 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insulin resistance is a characteristic feature of uremia." | 2.42 | Treatment of insulin resistance in uremia. ( Nesić, V; Stefanović, V; Stojimirović, B, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stefanović, V | 1 |
| Nesić, V | 1 |
| Stojimirović, B | 1 |
1 review available for 2,4-thiazolidinedione and Hyperparathyroidism
| Article | Year |
|---|---|
Treatment of insulin resistance in uremia.
Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Erythrop | 2003 |